BCAL Diagnostics is prepared to support an expedited Genetic Signatures and Microba merger, but only on revised terms, a GSS board reset and protections for a superior proposal. It may also provide up to $2 million in working capital to Microba, subject to raising the funds itself.
- 60:40 merger ratio in favour of Genetic Signatures
- Fiduciary out requested for a superior GSS proposal
- Up to $2 million of conditional Microba funding
- Support tied to GSS board restructure and chair resignation
BCAL Makes Merger Support Conditional
BCAL Diagnostics Limited (ASX:BDX), the largest shareholder in Genetic Signatures Limited (ASX:GSS), has put a possible rescue of the proposed GSS-Microba Life Sciences Limited (ASX:MAP) merger on a tightly defined footing. BCAL says it would consider supporting the transaction and an expedited approval process, but only after reviewing revised deal documents and provided no superior proposal for GSS emerges.
The position gives BCAL a substantial say in the next stage of a transaction that GSS and Microba said on 18 November was not proceeding. BCAL's earlier Genetic Signatures stake increase took its holding to 18.46%, according to the earlier announcement, making the shareholder's conditions difficult to ignore in any attempt to revive the combination.
60:40 Ratio and Fiduciary Protection Required
BCAL says any revised term sheet and scheme implementation deed would need to specify a 60:40 merger ratio in favour of GSS. It also wants GSS to receive a fiduciary out, allowing the company to withdraw from the merger without cost if a superior proposal appears.
That protection would be subject only to a break fee of no more than the 1% benchmark referenced in Takeovers Panel guidance. The proposed terms therefore address both the relative value allocated to GSS and the board's ability to consider an alternative transaction, rather than treating BCAL's support as an unconditional endorsement.
Up to $2 Million Funding Depends on Capital Raise
BCAL would also consider providing Microba with up to $2 million in working capital so the merger could proceed if approved by the two companies' shareholders and the Court. That funding is not committed: BCAL says it would first need to raise capital to finance it, while the proposed merger itself would still require the stated corporate and court approvals.
GSS Board Restructure Added to Conditions
BCAL has attached a governance demand to its position, requiring a restructure of the GSS board that includes the resignation of the GSS chair. The announcement does not identify any further proposed board changes or explain how the restructure would be implemented.
The immediate tests are consequently practical as well as financial: whether GSS and Microba produce revised documents acceptable to BCAL, whether a superior GSS proposal emerges, and whether BCAL can raise capital for the possible funding. Until those conditions are addressed, the merger remains a proposal BCAL may support rather than a transaction it has committed to deliver.
Bottom Line?
The merger's next decisive document may be the revised term sheet, but BCAL's support still depends on governance change, funding capacity and the absence of a better GSS offer.
Questions in the middle?
- Will GSS and Microba agree to the proposed 60:40 ratio and fiduciary out?
- Can BCAL raise the capital required for up to $2 million of Microba working capital?
- What board changes will GSS make, and will they satisfy BCAL?